BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168-175. [PMID: 17704357 DOI: 10.1148/radiol.2451070353] [Cited by in Crossref: 247] [Cited by in F6Publishing: 168] [Article Influence: 17.6] [Reference Citation Analysis]
Number Citing Articles
1 Husarik DB, Bashir MR, Weber PW, Nichols EB, Howle LE, Merkle EM, Nelson RC. Contrast-Enhanced Magnetic Resonance Angiography: First-Pass Arterial Enhancement as a Function of Gadolinium-Chelate Concentration, and the Saline Chaser Volume and Injection Rate. Investigative Radiology 2012;47:121-7. [DOI: 10.1097/rli.0b013e3182300603] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
2 Yusuf GT, Sellars ME, Deganello A, Cosgrove DO, Sidhu PS. Retrospective Analysis of the Safety and Cost Implications of Pediatric Contrast-Enhanced Ultrasound at a Single Center. AJR Am J Roentgenol. 2017;208:446-452. [PMID: 27959665 DOI: 10.2214/ajr.16.16700] [Cited by in Crossref: 59] [Cited by in F6Publishing: 20] [Article Influence: 11.8] [Reference Citation Analysis]
3 Weinreb JC, Kuo PH. Nephrogenic Systemic Fibrosis. Magnetic Resonance Imaging Clinics of North America 2009;17:159-67. [DOI: 10.1016/j.mric.2009.01.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
4 Kalb B, Votaw JR, Salman K, Sharma P, Martin DR. Magnetic resonance nephrourography: current and developing techniques. Radiol Clin North Am. 2008;46:11-24, v. [PMID: 18328877 DOI: 10.1016/j.rcl.2008.01.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
5 Lohan DG, Tomasian A, Saleh RS, Singhal A, Krishnam MS, Finn JP. Ultra-low-dose, time-resolved contrast-enhanced magnetic resonance angiography of the carotid arteries at 3.0 tesla. Invest Radiol 2009;44:207-17. [PMID: 19300100 DOI: 10.1097/RLI.0b013e31819ca048] [Cited by in Crossref: 26] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
6 Tumkosit M, Puntawangkoon C, Morgan TM, Clark HP, Hamilton CA, Ntim WO, Clark PB, Hundley WG. Left ventricular infarct size assessed with 0.1 mmol/kg of gadobenate dimeglumine correlates with that assessed with 0.2 mmol/kg of gadopentetate dimeglumine. J Comput Assist Tomogr 2009;33:328-33. [PMID: 19478622 DOI: 10.1097/RCT.0b013e318187fed0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
7 Föller M, Sopjani M, Schlemmer HP, Claussen CD, Lang F. Triggering of suicidal erythrocyte death by radiocontrast agents. Eur J Clin Invest 2009;39:576-83. [PMID: 19397685 DOI: 10.1111/j.1365-2362.2009.02140.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
8 Yokoo T, Collins JM, Hanna RF, Bydder M, Middleton MS, Sirlin CB. Effects of intravenous gadolinium administration and flip angle on the assessment of liver fat signal fraction with opposed-phase and in-phase imaging. J Magn Reson Imaging 2008;28:246-51. [DOI: 10.1002/jmri.21375] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
9 Sieber MA, Steger-hartmann T, Lengsfeld P, Pietsch H. Gadolinium-based contrast agents and NSF: Evidence from animal experience. J Magn Reson Imaging 2009;30:1268-76. [DOI: 10.1002/jmri.21971] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 6.1] [Reference Citation Analysis]
10 Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: A summary of the medical literature reporting. European Journal of Radiology 2008;66:230-4. [DOI: 10.1016/j.ejrad.2008.02.011] [Cited by in Crossref: 223] [Cited by in F6Publishing: 149] [Article Influence: 17.2] [Reference Citation Analysis]
11 Yu H, Lou H, Zou T, Wang X, Jiang S, Huang Z, Du Y, Jiang C, Ma L, Zhu J, He W, Rui Q, Zhou J, Wen Z. Applying protein-based amide proton transfer MR imaging to distinguish solitary brain metastases from glioblastoma. Eur Radiol 2017;27:4516-24. [PMID: 28534162 DOI: 10.1007/s00330-017-4867-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 6.8] [Reference Citation Analysis]
12 Baessler B, Mannil M, Oebel S, Maintz D, Alkadhi H, Manka R. Subacute and Chronic Left Ventricular Myocardial Scar: Accuracy of Texture Analysis on Nonenhanced Cine MR Images. Radiology 2018;286:103-12. [PMID: 28836886 DOI: 10.1148/radiol.2017170213] [Cited by in Crossref: 79] [Cited by in F6Publishing: 55] [Article Influence: 19.8] [Reference Citation Analysis]
13 Bolskar RD. Gadofullerene MRI contrast agents. Nanomedicine 2008;3:201-13. [DOI: 10.2217/17435889.3.2.201] [Cited by in Crossref: 185] [Cited by in F6Publishing: 86] [Article Influence: 14.2] [Reference Citation Analysis]
14 Thomson PC, Collidge TA, Mark PB, Traynor JP. Gadolinium contrast may be risky in kidney disease. BMJ 2007;334:1335-6. [PMID: 17599982 DOI: 10.1136/bmj.39254.924641.1F] [Reference Citation Analysis]
15 Dehkharghani S, Qiu D, Albin LS, Saindane AM. Dose Reduction in Contrast-Enhanced Cervical MR Angiography: Field Strength Dependency of Vascular Signal Intensity, Contrast Administration, and Arteriographic Quality. American Journal of Roentgenology 2015;204:W701-6. [DOI: 10.2214/ajr.14.13435] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
16 Perazella MA. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Curr Opin Nephrol Hypertens 2009;18:519-25. [PMID: 19623065 DOI: 10.1097/MNH.0b013e3283309660] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
17 Raczeck P, Fries P, Bücker A, Schneider G. [Gadolinium deposition-"gadolinium deposition disease"]. Radiologe 2019;59:435-43. [PMID: 30963195 DOI: 10.1007/s00117-019-0522-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Zhang B, Liang L, Chen W, Liang C, Zhang S. An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis. PLoS One 2015;10:e0129720. [PMID: 26076348 DOI: 10.1371/journal.pone.0129720] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
19 Thomsen HS. Nephrogenic Systemic Fibrosis: NEPHROGENIC SYSTEMIC FIBROSIS. Imaging Decisions MRI 2008;11:13-8. [DOI: 10.1111/j.1617-0830.2007.00110.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
20 Shen ZT, Zheng S, Gounis MJ, Sigalov AB. Diagnostic Magnetic Resonance Imaging of Atherosclerosis in Apolipoprotein E Knockout Mouse Model Using Macrophage-Targeted Gadolinium-Containing Synthetic Lipopeptide Nanoparticles. PLoS One 2015;10:e0143453. [PMID: 26569115 DOI: 10.1371/journal.pone.0143453] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
21 Grobner T, Prischl FC. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Semin Dial 2008;21:135-9. [PMID: 18226001 DOI: 10.1111/j.1525-139X.2007.00406.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
22 Fiorino G, Bonifacio C, Malesci A, Balzarini L, Danese S. MRI in Crohn’s disease--current and future clinical applications. Nat Rev Gastroenterol Hepatol. 2012;9:23-31. [PMID: 22105109 DOI: 10.1038/nrgastro.2011.214] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
23 Chrysochou C, Buckley DL, Dark P, Cowie A, Kalra PA. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging 2009;29:887-94. [PMID: 19306428 DOI: 10.1002/jmri.21708] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
24 Zou Z, Ma L, Li H. Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital. J Magn Reson Imaging 2009;30:1309-12. [DOI: 10.1002/jmri.21769] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
25 Wang J, Yan F, Liu J, Lu J, Li D, Luan J, Wang X, Li Y, Iezzi R, De Cobelli F. Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR angiography of the peripheral arteries (the Peripheral VALUE Study). J Magn Reson Imaging 2013;38:926-37. [PMID: 23371919 DOI: 10.1002/jmri.24040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
26 Wheaton AJ, Miyazaki M. Non-contrast enhanced MR angiography: Physical principles. J Magn Reson Imaging 2012;36:286-304. [DOI: 10.1002/jmri.23641] [Cited by in Crossref: 90] [Cited by in F6Publishing: 48] [Article Influence: 10.0] [Reference Citation Analysis]
27 Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 2010;256:735-43. [PMID: 20663970 DOI: 10.1148/radiol.10091131] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
28 Nadjiri J, Pfeiffer D, Straeter AS, Noël PB, Fingerle A, Eckstein HH, Laugwitz KL, Rummeny EJ, Braren R, Rasper M. Spectral Computed Tomography Angiography With a Gadolinium-based Contrast Agent: First Clinical Imaging Results in Cardiovascular Applications. J Thorac Imaging 2018;33:246-53. [PMID: 29863589 DOI: 10.1097/RTI.0000000000000335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
29 Wang J, Zhang H, Ni D, Fan W, Qu J, Liu Y, Jin Y, Cui Z, Xu T, Wu Y, Bu W, Yao Z. High-Performance Upconversion Nanoprobes for Multimodal MR Imaging of Acute Ischemic Stroke. Small 2016;12:3591-600. [PMID: 27219071 DOI: 10.1002/smll.201601144] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
30 Rees O, Agarwal SK. Nephrogenic systemic fibrosis: UK survey of the use of gadolinium-based contrast media. Clin Radiol 2010;65:636-41. [PMID: 20599066 DOI: 10.1016/j.crad.2010.04.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
31 Gauden AJ, Phal PM, Drummond KJ. MRI safety: nephrogenic systemic fibrosis and other risks. J Clin Neurosci 2010;17:1097-104. [PMID: 20542435 DOI: 10.1016/j.jocn.2010.01.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
32 Semelka RC, Prybylski JP, Ramalho M. Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents. Magn Reson Imaging 2019;58:174-8. [PMID: 30471330 DOI: 10.1016/j.mri.2018.11.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
33 Attari H, Cao Y, Elmholdt TR, Zhao Y, Prince MR. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. Radiology. 2019;292:376-386. [PMID: 31264946 DOI: 10.1148/radiol.2019182916] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 21.5] [Reference Citation Analysis]
34 Behera PS, Vasanthavel S, Ponnilavan V, Kannan S. Influence of gadolinium content on the tetragonal to cubic phase transition in zirconia-silica binary oxides. Journal of Solid State Chemistry 2015;225:305-9. [DOI: 10.1016/j.jssc.2014.12.029] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
35 Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC Cardiovasc Imaging 2011;4:1206-16. [PMID: 22093272 DOI: 10.1016/j.jcmg.2011.08.013] [Cited by in Crossref: 70] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
36 Peldschus K, Hamdorf M, Robert P, Port M, Graessner J, Adam G, Herborn CU. Contrast-Enhanced Magnetic Resonance Angiography: Evaluation of the High Relaxivity Low Diffusible Gadolinium-Based Contrast Agent P846 in Comparison With Gadoterate Meglumine in Rabbits at 1.5 Tesla and 3.0 Tesla. Investigative Radiology 2008;43:837-42. [DOI: 10.1097/rli.0b013e3181852158] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
37 Gillis KA, McComb C, Foster JE, Taylor AH, Patel RK, Morris ST, Jardine AG, Schneider MP, Roditi GH, Delles C, Mark PB. Inter-study reproducibility of arterial spin labelling magnetic resonance imaging for measurement of renal perfusion in healthy volunteers at 3 Tesla. BMC Nephrol 2014;15:23. [PMID: 24484613 DOI: 10.1186/1471-2369-15-23] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
38 Amet S, Launay-Vacher V, Clément O, Frances C, Tricotel A, Stengel B, Gauvrit JY, Grenier N, Reinhardt G, Janus N, Choukroun G, Laville M, Deray G. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study. Invest Radiol 2014;49:109-15. [PMID: 24169070 DOI: 10.1097/RLI.0000000000000000] [Cited by in Crossref: 53] [Cited by in F6Publishing: 10] [Article Influence: 7.6] [Reference Citation Analysis]
39 Kitajima K, Maeda T, Watanabe S, Ueno Y, Sugimura K. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents. Int J Urol 2012;19:806-11. [PMID: 22571387 DOI: 10.1111/j.1442-2042.2012.03042.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
40 Leiner T, Kucharczyk W. Special issue: nephrogenic systemic fibrosis. J Magn Reson Imaging 2009;30:1233-5. [PMID: 19938034 DOI: 10.1002/jmri.21985] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
41 Bryant B, Im K, Broome D. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. Clinical Radiology 2009;64:706-13. [DOI: 10.1016/j.crad.2009.04.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
42 Roemer FW, Guermazi A, Zhang Y, Yang M, Hunter DJ, Crema MD, Bohndorf K. Hoffa's Fat Pad: Evaluation on Unenhanced MR Images as a Measure of Patellofemoral Synovitis in Osteoarthritis. AJR Am J Roentgenol 2009;192:1696-700. [PMID: 19457837 DOI: 10.2214/AJR.08.2038] [Cited by in Crossref: 73] [Cited by in F6Publishing: 31] [Article Influence: 6.1] [Reference Citation Analysis]
43 Ganguli S, Pedrosa I, Smith MP, Niendorf ER, Fredericks S, Rofsky NM. Low Dose Pedal Magnetic Resonance Angiography at 3 Tesla With Time-Resolved Imaging of Contrast Kinetics: A Feasibility Study. Investigative Radiology 2008;43:650-5. [DOI: 10.1097/rli.0b013e31817ed1e3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
44 Thomson LK, Thomson PC, Kingsmore DB, Blessing K, Daly CD, Cowper SE, Roditi GH. Diagnosing nephrogenic systemic fibrosis in the post-FDA restriction era: NSF in the Post-FDA Restriction ERA. J Magn Reson Imaging 2015;41:1268-71. [DOI: 10.1002/jmri.24664] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
45 Bleavins K, Perone P, Naik M, Rehman M, Aslam MN, Dame MK, Meshinchi S, Bhagavathula N, Varani J. Stimulation of fibroblast proliferation by insoluble gadolinium salts. Biol Trace Elem Res 2012;145:257-67. [PMID: 21882070 DOI: 10.1007/s12011-011-9176-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
46 Thomsen HS, Marckmann P. Extracellular Gd-CA: differences in prevalence of NSF. Eur J Radiol. 2008;66:180-183. [PMID: 18342468 DOI: 10.1016/j.ejrad.2008.01.024] [Cited by in Crossref: 61] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
47 Ponrartana S, Moore MM, Chan SS, Victoria T, Dillman JR, Chavhan GB. Safety issues related to intravenous contrast agent use in magnetic resonance imaging. Pediatr Radiol 2021;51:736-47. [PMID: 33871726 DOI: 10.1007/s00247-020-04896-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Kaewlai R, Abujudeh H. Nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2012;199:W17-W23. [PMID: 22733927 DOI: 10.2214/ajr.11.8144] [Cited by in Crossref: 78] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
49 Riccabona M, Dacher J, Olsen ØE, Claudon M, Fotter R. Gadolinium and Nephrogenic Systemic Fibrosis. In: Fotter R, editor. Pediatric Uroradiology. Berlin: Springer Berlin Heidelberg; 2008. pp. 515-7. [DOI: 10.1007/978-3-540-33005-9_29] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Bridges MD, St. Amant BS, Mcneil RB, Cernigliaro JG, Dwyer JP, Fitzpatrick PM. High-Dose Gadodiamide for Catheter Angiography and CT in Patients With Varying Degrees of Renal Insufficiency: Prevalence of Subsequent Nephrogenic Systemic Fibrosis and Decline in Renal Function. American Journal of Roentgenology 2009;192:1538-43. [DOI: 10.2214/ajr.07.3895] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
51 Penfield JG, Reilly RF. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis Risk: Is There a Difference between Gadolinium-Based Contrast Agents?: GADOLINIUM CHELATE DIFFERENCES AND NSF RISK. Seminars in Dialysis 2008;21:129-34. [DOI: 10.1111/j.1525-139x.2007.00408.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
52 Becker S, Walter S, Witzke O, Kreuter A, Kribben A, Mitchell A. Application of Gadolinium-Based Contrast Agents and Prevalence of Nephrogenic Systemic Fibrosis in a Cohort of End-Stage Renal Disease Patients on Hemodialysis. Nephron Clin Pract 2012;121:c91-4. [DOI: 10.1159/000345150] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
53 Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol. 2009;4:461-469. [PMID: 19201920 DOI: 10.2215/cjn.06011108] [Cited by in Crossref: 178] [Cited by in F6Publishing: 62] [Article Influence: 14.8] [Reference Citation Analysis]
54 Langer RD, Lorke DE, Neidl van Gorkom KF, Petroianu G, Azimullah S, Nurulain SM, Singh S, Fuchsjäger M. In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents. Eur J Radiol 2012;81:2562-7. [PMID: 22304979 DOI: 10.1016/j.ejrad.2011.10.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
55 Hoggard N, Roditi GH. T1 hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition? Br J Radiol 2017;90:20160590. [PMID: 27653560 DOI: 10.1259/bjr.20160590] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
56 Piera-Velazquez S, Louneva N, Fertala J, Wermuth PJ, Del Galdo F, Jimenez SA. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69:2017-23. [PMID: 20570839 DOI: 10.1136/ard.2009.127761] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
57 Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 2008;51:966-75. [PMID: 18501784 DOI: 10.1053/j.ajkd.2007.12.036] [Cited by in Crossref: 73] [Cited by in F6Publishing: 52] [Article Influence: 5.6] [Reference Citation Analysis]
58 Lim RP, Jacob JS, Hecht EM, Kim DC, Huffman SD, Kim S, Babb JS, Laub G, Adelman MA, Lee VS. Time-resolved lower extremity MRA with temporal interpolation and stochastic spiral trajectories: preliminary clinical experience. J Magn Reson Imaging 2010;31:663-72. [PMID: 20187210 DOI: 10.1002/jmri.22108] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
59 Bahrami S, Raman SS, Sauk S, Salehmoghaddam S, Villablanca JP, Finn JP, Lu DS. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors. J Comput Assist Tomogr 2009;33:819-23. [PMID: 19940643 DOI: 10.1097/RCT.0b013e31819d68ed] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
60 Nael K, Moriarty JM, Finn JP. Low dose CE-MRA. Eur J Radiol 2011;80:2-8. [PMID: 21458187 DOI: 10.1016/j.ejrad.2011.01.092] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
61 Prince MR, Zhang HL, Roditi GH, Leiner T, Kucharczyk W. Risk factors for NSF: a literature review. J Magn Reson Imaging. 2009;30:1298-1308. [PMID: 19937930 DOI: 10.1002/jmri.21973] [Cited by in Crossref: 94] [Cited by in F6Publishing: 68] [Article Influence: 8.5] [Reference Citation Analysis]
62 Perazella MA. How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease? Clin J Am Soc Nephrol 2008;3:649-51. [PMID: 18385396 DOI: 10.2215/CJN.00670208] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
63 Grainger RG, Thomsen HS, Morcos SK, Koh D, Roditi G. Intravascular Contrast Media for Radiology, CT and MRI. Grainger &amp Allison's Diagnostic Radiology. Elsevier; 2008. pp. 31-53. [DOI: 10.1016/b978-0-443-10163-2.50005-1] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
64 Stoumpos S, Hennessy M, Vesey AT, Radjenovic A, Kasthuri R, Kingsmore DB, Mark PB, Roditi G. Ferumoxytol-enhanced magnetic resonance angiography for the assessment of potential kidney transplant recipients. Eur Radiol 2018;28:115-23. [PMID: 28677065 DOI: 10.1007/s00330-017-4934-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
65 Brown MC, Simpson K, Kerssens JJ, Mactier RA; Scottish Renal Registry. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol 2009;4:1222-9. [PMID: 19541815 DOI: 10.2215/CJN.01260209] [Cited by in Crossref: 135] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
66 Sieber MA, Lengsfeld P, Walter J, Schirmer H, Frenzel T, Siegmund F, Weinmann HJ, Pietsch H. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging 2008;27:955-62. [PMID: 18425843 DOI: 10.1002/jmri.21368] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
67 Tomasian A, Salamon N, Lohan DG, Jalili M, Villablanca JP, Finn JP. Supraaortic arteries: contrast material dose reduction at 3.0-T high-spatial-resolution MR angiography--feasibility study. Radiology 2008;249:980-90. [PMID: 19011192 DOI: 10.1148/radiol.2493080209] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
68 Song KD, Kim SH, Lee J, Kang KA, Kim J, Yoo H. Half-dose gadoxetic acid-enhanced liver magnetic resonance imaging in patients at risk for nephrogenic systemic fibrosis. European Journal of Radiology 2015;84:378-83. [DOI: 10.1016/j.ejrad.2014.12.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
69 Kelly DM, Ademi Z, Doehner W, Lip GYH, Mark P, Toyoda K, Wong CX, Sarnak M, Cheung M, Herzog CA, Johansen KL, Reinecke H, Sood MM. Chronic Kidney Disease and Cerebrovascular Disease: Consensus and Guidance From a KDIGO Controversies Conference. Stroke 2021;52:e328-46. [PMID: 34078109 DOI: 10.1161/STROKEAHA.120.029680] [Reference Citation Analysis]
70 Altun E, Martin DR, Wertman R, Lugo-somolinos A, Fuller ER, Semelka RC. Nephrogenic Systemic Fibrosis: Change in Incidence Following a Switch in Gadolinium Agents and Adoption of a Gadolinium Policy—Report from Two U.S. Universities. Radiology 2009;253:689-96. [DOI: 10.1148/radiol.2533090649] [Cited by in Crossref: 112] [Cited by in F6Publishing: 64] [Article Influence: 9.3] [Reference Citation Analysis]
71 Hope TA, High WA, Leboit PE, Chaopathomkul B, Rogut VS, Herfkens RJ, Brasch RC. Nephrogenic Systemic Fibrosis in Rats Treated with Erythropoietin and Intravenous Iron. Radiology 2009;253:390-8. [DOI: 10.1148/radiol.2532090580] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
72 Heinz-Peer G, Neruda A, Watschinger B, Vychytil A, Geusau A, Haumer M, Weber M. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease. Eur J Radiol 2010;76:129-34. [PMID: 19619969 DOI: 10.1016/j.ejrad.2009.06.028] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
73 Tsushima Y, Kanal E, Thomsen HS. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases. Br J Radiol 2010;83:590-5. [PMID: 20413447 DOI: 10.1259/bjr/17689538] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
74 Kuo PH. NSF-active and NSF-inert species of gadolinium: mechanistic and clinical implications. AJR Am J Roentgenol 2008;191:1861-3. [PMID: 19020260 DOI: 10.2214/AJR.08.1179] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
75 Xiao B, Wang P, Zhao Y, Liu Y, Ye Z. Combination of diffusion-weighted imaging and arterial spin labeling at 3.0 T for the clinical staging of nasopharyngeal carcinoma. Clin Imaging 2020;66:127-32. [PMID: 32480267 DOI: 10.1016/j.clinimag.2020.05.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Hammon M, Janka R, Siegl C, Seuss H, Grosso R, Martirosian P, Schmieder RE, Uder M, Kistner I. Reproducibility of Kidney Perfusion Measurements With Arterial Spin Labeling at 1.5 Tesla MRI Combined With Semiautomatic Segmentation for Differential Cortical and Medullary Assessment. Medicine (Baltimore) 2016;95:e3083. [PMID: 26986143 DOI: 10.1097/MD.0000000000003083] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
77 Maki JH, Wang M, Wilson GJ, Shutske MG, Leiner T. Highly accelerated first-pass contrast-enhanced magnetic resonance angiography of the peripheral vasculature: Comparison of gadofosveset trisodium with gadopentetate dimeglumine contrast agents. J Magn Reson Imaging 2009;30:1085-92. [DOI: 10.1002/jmri.21961] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
78 Yu H, Wen X, Wu P, Chen Y, Zou T, Wang X, Jiang S, Zhou J, Wen Z. Can amide proton transfer-weighted imaging differentiate tumor grade and predict Ki-67 proliferation status of meningioma? Eur Radiol 2019;29:5298-306. [PMID: 30887206 DOI: 10.1007/s00330-019-06115-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
79 van der Molen A. Nephrogenic systemic fibrosis and the role of gadolinium contrast media. Journal of Medical Imaging and Radiation Oncology 2008;52:339-50. [DOI: 10.1111/j.1440-1673.2008.01965.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
80 Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN. Nephrogenic Systemic Fibrosis and Its Impact on Abdominal Imaging. RadioGraphics 2009;29:1565-74. [DOI: 10.1148/rg.296095517] [Cited by in Crossref: 66] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
81 Weinreb JC. Which Study When? Is Gadolinium-enhanced MR Imaging Safer than Iodine-enhanced CT? 1. Radiology 2008;249:3-8. [DOI: 10.1148/radiol.2491080075] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
82 Saritas EU, Goodwill PW, Croft LR, Konkle JJ, Lu K, Zheng B, Conolly SM. Magnetic particle imaging (MPI) for NMR and MRI researchers. J Magn Reson 2013;229:116-26. [PMID: 23305842 DOI: 10.1016/j.jmr.2012.11.029] [Cited by in Crossref: 164] [Cited by in F6Publishing: 90] [Article Influence: 18.2] [Reference Citation Analysis]
83 Brambilla S, Valaperta S, Graziani G, Montanelli A. Gadolinium and lanthanum: A iatrogenic transmetallation? Clinical Biochemistry 2008;41:1029-33. [DOI: 10.1016/j.clinbiochem.2008.05.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
84 Lansberg MG, Thijs VN, Bammer R, Olivot JM, Marks MP, Wechsler LR, Kemp S, Albers GW. The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusion. Stroke. 2008;39:2491-2496. [PMID: 18635861 DOI: 10.1161/strokeaha.107.508572] [Cited by in Crossref: 81] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
85 Rofsky NM, Sherry AD, Lenkinski RE. Nephrogenic Systemic Fibrosis: A Chemical Perspective. Radiology 2008;247:608-12. [DOI: 10.1148/radiol.2473071975] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 4.8] [Reference Citation Analysis]
86 Alhadad A, Sterner G, Svensson Å, Alhadad H, Leander P. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden. Scandinavian Journal of Urology and Nephrology 2012;46:48-53. [DOI: 10.3109/00365599.2011.621142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
87 Bhave G, Lewis JB, Chang SS. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. J Urol 2008;180:830-5; discussion 835. [PMID: 18635232 DOI: 10.1016/j.juro.2008.05.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
88 Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 2008;21:123-8. [PMID: 18226008 DOI: 10.1111/j.1525-139X.2007.00399.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
89 Tsai LL, Grant AK, Mortele KJ, Kung JW, Smith MP. A Practical Guide to MR Imaging Safety: What Radiologists Need to Know. Radiographics 2015;35:1722-37. [PMID: 26466181 DOI: 10.1148/rg.2015150108] [Cited by in Crossref: 64] [Cited by in F6Publishing: 33] [Article Influence: 12.8] [Reference Citation Analysis]
90 Baker ME, Einstein DM, Veniero JC. Computed tomography enterography and magnetic resonance enterography: the future of small bowel imaging. Clin Colon Rectal Surg. 2008;21:193-212. [PMID: 20011418 DOI: 10.1055/s-2008-1080999] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
91 Poschenrieder F, Hamer OW, Herold T, Schleicher T, Borisch I, Feuerbach S, Zorger N. Diagnostic accuracy of intraarterial and i.v. MR angiography for the detection of stenoses of the infrainguinal arteries. AJR Am J Roentgenol 2009;192:117-21. [PMID: 19098189 DOI: 10.2214/AJR.08.1230] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Matsumoto Y, Mitsuhashi Y, Monma F, Kawaguchi M, Suzuki T, Miyabe C, Igarashi A, Tsuboi R. Nephrogenic systemic fibrosis: a case report and review on Japanese patients. J Dermatol 2012;39:449-53. [PMID: 22035371 DOI: 10.1111/j.1346-8138.2011.01407.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
93 Yang WQ, Cui XL, Zhang M, Yuan XD, Ying L, Li FH, Li HL. Preoperative evaluation of iliac blood vessels for first kidney transplant recipients: Combination of conventional and contrast-enhanced ultrasonography. Clin Hemorheol Microcirc 2021;78:139-49. [PMID: 33554892 DOI: 10.3233/CH-201054] [Reference Citation Analysis]
94 Shabana WM, Cohan RH, Ellis JH, Hussain HK, Francis IR, Su LD, Mukherji SK, Swartz RD. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol. 2008;190:736-741. [PMID: 18287446 DOI: 10.2214/ajr.07.3115] [Cited by in Crossref: 94] [Cited by in F6Publishing: 14] [Article Influence: 7.2] [Reference Citation Analysis]
95 Agarwal R, Brunelli SM, Williams K, Mitchell MD, Feldman HI, Umscheid CA. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant 2009;24:856-63. [PMID: 18952698 DOI: 10.1093/ndt/gfn593] [Cited by in Crossref: 108] [Cited by in F6Publishing: 74] [Article Influence: 8.3] [Reference Citation Analysis]
96 Dünger D, Krause M, Gräfe D, Merkenschlager A, Roth C, Sorge I. Do we need gadolinium-based contrast medium for brain magnetic resonance imaging in children? Pediatr Radiol 2018;48:858-64. [DOI: 10.1007/s00247-017-3999-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
97 Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, DeLapaz RL, Lee HJ, Magro CM, Valeri AM. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248:807-816. [PMID: 18710976 DOI: 10.1148/radiol.2483071863] [Cited by in Crossref: 226] [Cited by in F6Publishing: 152] [Article Influence: 17.4] [Reference Citation Analysis]
98 Telgmann L, Sperling M, Karst U. Determination of gadolinium-based MRI contrast agents in biological and environmental samples: A review. Analytica Chimica Acta 2013;764:1-16. [DOI: 10.1016/j.aca.2012.12.007] [Cited by in Crossref: 73] [Cited by in F6Publishing: 38] [Article Influence: 9.1] [Reference Citation Analysis]
99 Hinkmann FM, Voit HL, Anders K, Baum U, Seidensticker P, Bautz WA, Lell MM. Ultra-fast carotid CT-angiography: low versus standard volume contrast material protocol for a 128-slice CT-system. Invest Radiol 2009;44:257-64. [PMID: 19550377 DOI: 10.1097/RLI.0b013e31819b08a0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
100 Wertman R, Altun E, Martin DR, Mitchell DG, Leyendecker JR, O'malley RB, Parsons DJ, Fuller ER, Semelka RC. Risk of Nephrogenic Systemic Fibrosis: Evaluation of Gadolinium Chelate Contrast Agents at Four American Universities. Radiology 2008;248:799-806. [DOI: 10.1148/radiol.2483072093] [Cited by in Crossref: 138] [Cited by in F6Publishing: 109] [Article Influence: 10.6] [Reference Citation Analysis]
101 DaSilva M, O'Brien Deming M, Fligiel SE, Dame MK, Johnson KJ, Swartz RD, Varani J. Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol 2010;45:733-9. [PMID: 20661146 DOI: 10.1097/RLI.0b013e3181e9436b] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
102 Parienty I, Rostoker G, Jouniaux F, Piotin M, Admiraal-Behloul F, Miyazaki M. Renal artery stenosis evaluation in chronic kidney disease patients: nonenhanced time-spatial labeling inversion-pulse three-dimensional MR angiography with regulated breathing versus DSA. Radiology 2011;259:592-601. [PMID: 21330564 DOI: 10.1148/radiol.11101422] [Cited by in Crossref: 36] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
103 Anzidei M, Napoli A, Marincola BC, Nofroni I, Geiger D, Zaccagna F, Catalano C, Passariello R. Gadofosveset-enhanced MR angiography of carotid arteries: does steady-state imaging improve accuracy of first-pass imaging? Comparison with selective digital subtraction angiography. Radiology 2009;251:457-66. [PMID: 19401574 DOI: 10.1148/radiol.2512081197] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
104 Idée JM, Port M, Medina C, Lancelot E, Fayoux E, Ballet S, Corot C. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008;248:77-88. [PMID: 18440117 DOI: 10.1016/j.tox.2008.03.012] [Cited by in Crossref: 114] [Cited by in F6Publishing: 76] [Article Influence: 8.8] [Reference Citation Analysis]
105 Bruno F, DeAguero J, Do C, Lee DY, Tan C, Escobar GP, Wagner B. Overlapping roles of NADPH oxidase 4 for diabetic and gadolinium-based contrast agent-induced systemic fibrosis. Am J Physiol Renal Physiol 2021;320:F617-27. [PMID: 33615889 DOI: 10.1152/ajprenal.00456.2020] [Reference Citation Analysis]
106 Tsushima Y, Takahashi-taketomi A, Endo K. Nephrogenic Systemic Fibrosis in Japan: Advisability of Keeping the Administered Dose as Low as Possible. Radiology 2008;247:915-6. [DOI: 10.1148/radiol.2473072101] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
107 Perazella MA, Reilly RF. Imaging patients with kidney disease: how do we approach contrast-related toxicity? Am J Med Sci 2011;341:215-21. [PMID: 21139495 DOI: 10.1097/MAJ.0b013e3181f016e6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
108 Williams LR, Oldale MJ, Bradley AJ. Imaging renal masses and staging renal tumours. Imaging 2008;20:73-86. [DOI: 10.1259/imaging/16349669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
109 Elmholdt TR, Olesen AB, Jørgensen B, Kvist S, Skov L, Thomsen HS, Marckmann P, Pedersen M. Nephrogenic systemic fibrosis in Denmark--a nationwide investigation. PLoS One 2013;8:e82037. [PMID: 24349178 DOI: 10.1371/journal.pone.0082037] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
110 He JQ, Iv M, Li G, Zhang M, Hayden Gephart M. Noncontrast T2-Weighted Magnetic Resonance Imaging Sequences for Long-Term Monitoring of Asymptomatic Convexity Meningiomas. World Neurosurgery 2020;135:e100-5. [DOI: 10.1016/j.wneu.2019.11.051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
111 Semelka RC, Ramalho M, Alobaidy M, Ramalho J. Gadolinium in Humans: A Family of Disorders. American Journal of Roentgenology 2016;207:229-33. [DOI: 10.2214/ajr.15.15842] [Cited by in Crossref: 62] [Cited by in F6Publishing: 11] [Article Influence: 12.4] [Reference Citation Analysis]
112 Zou Z, Ma L. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. Indian J Dermatol. 2011;56:65-73. [PMID: 21572796 DOI: 10.4103/0019-5154.77556] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
113 Fiorino G, Bonifacio C, Malesci A, Balzarini L, Danese S. MRI in Crohn’s disease--current and future clinical applications. Nat Rev Gastroenterol Hepatol. 2012;9:23-31. [PMID: 22105109 DOI: 10.1038/nrgastro.2011.2142] [Reference Citation Analysis]
114 Telgmann L, Wehe CA, Künnemeyer J, Bülter A, Sperling M, Karst U. Speciation of Gd-based MRI contrast agents and potential products of transmetalation with iron ions or parenteral iron supplements. Anal Bioanal Chem 2012;404:2133-41. [DOI: 10.1007/s00216-012-6404-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
115 Baeßler B, Mannil M, Maintz D, Alkadhi H, Manka R. Texture analysis and machine learning of non-contrast T1-weighted MR images in patients with hypertrophic cardiomyopathy-Preliminary results. Eur J Radiol 2018;102:61-7. [PMID: 29685546 DOI: 10.1016/j.ejrad.2018.03.013] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 16.0] [Reference Citation Analysis]
116 Lindley MD, Kim D, Morrell G, Heilbrun ME, Storey P, Hanrahan CJ, Lee VS. High-permittivity thin dielectric padding improves fresh blood imaging of femoral arteries at 3 T. Invest Radiol 2015;50:101-7. [PMID: 25329606 DOI: 10.1097/RLI.0000000000000106] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
117 Xiao B, Wang P, Zhao Y, Liu Y, Ye Z. Nasopharyngeal carcinoma perfusion MRI: Comparison of arterial spin labeling and dynamic contrast-enhanced MRI. Medicine (Baltimore) 2020;99:e20503. [PMID: 32481470 DOI: 10.1097/MD.0000000000020503] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
118 Stollenwerk MM, Pashkunova-martic I, Kremser C, Talasz H, Thurner GC, Abdelmoez AA, Wallnöfer EA, Helbok A, Neuhauser E, Klammsteiner N, Klimaschewski L, Guggenberg E, Fröhlich E, Keppler B, Jaschke W, Debbage P. Albumin-based nanoparticles as magnetic resonance contrast agents: I. Concept, first syntheses and characterisation. Histochem Cell Biol 2010;133:375-404. [DOI: 10.1007/s00418-010-0676-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
119 Persu A, Giavarini A, Touzé E, Januszewicz A, Sapoval M, Azizi M, Barral X, Jeunemaitre X, Morganti A, Plouin PF, de Leeuw P; ESH Working Group Hypertension and the Kidney. European consensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens 2014;32:1367-78. [PMID: 24842696 DOI: 10.1097/HJH.0000000000000213] [Cited by in Crossref: 118] [Cited by in F6Publishing: 13] [Article Influence: 19.7] [Reference Citation Analysis]
120 Xie M, Wang Z, Lu Q, Nie S, Butch CJ, Wang Y, Dai B. Ultracompact Iron Oxide Nanoparticles with a Monolayer Coating of Succinylated Heparin: A New Class of Renal-Clearable and Nontoxic T1 Agents for High-Field MRI. ACS Appl Mater Interfaces 2020. [PMID: 33210906 DOI: 10.1021/acsami.0c12454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
121 Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, Walter J, Weinmann HJ, Pietsch H. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008;18:2164-73. [PMID: 18545998 DOI: 10.1007/s00330-008-0977-y] [Cited by in Crossref: 153] [Cited by in F6Publishing: 121] [Article Influence: 11.8] [Reference Citation Analysis]
122 Todd DJ, Kay J. Nephrogenic systemic fibrosis: An epidemic of gadolinium toxicity. Curr Rheumatol Rep 2008;10:195-204. [DOI: 10.1007/s11926-008-0033-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
123 Zhang HL, Sos TA, Winchester PA, Gao J, Prince MR. Renal Artery Stenosis: Imaging Options, Pitfalls, and Concerns. Progress in Cardiovascular Diseases 2009;52:209-19. [DOI: 10.1016/j.pcad.2009.10.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
124 Jalandhara N, Arora R, Batuman V. Nephrogenic Systemic Fibrosis and Gadolinium-Containing Radiological Contrast Agents: An Update. Clin Pharmacol Ther 2011;89:920-3. [DOI: 10.1038/clpt.2010.346] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
125 Kim KH, Fonda JR, Lawler EV, Gagnon D, Kaufman JS. Change in use of gadolinium-enhanced magnetic resonance studies in kidney disease patients after US Food and Drug Administration warnings: a cross-sectional study of Veterans Affairs Health Care System data from 2005-2008. Am J Kidney Dis 2010;56:458-67. [PMID: 20580477 DOI: 10.1053/j.ajkd.2010.03.027] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
126 Fries P, Runge VM, Bücker A, Schürholz H, Reith W, Robert P, Jackson C, Lanz T, Schneider G. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model. Invest Radiol. 2009;44:200-206. [PMID: 19300099 DOI: 10.1097/rli.0b013e31819817ff] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
127 Mendichovszky IA, Marks SD, Simcock CM, Olsen OE. Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. Pediatr Radiol. 2008;38:489-496; quiz 602-603. [PMID: 17943276 DOI: 10.1007/s00247-007-0633-8] [Cited by in Crossref: 71] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
128 Telgmann L, Faber H, Jahn S, Melles D, Simon H, Sperling M, Karst U. Identification and quantification of potential metabolites of Gd-based contrast agents by electrochemistry/separations/mass spectrometry. Journal of Chromatography A 2012;1240:147-55. [DOI: 10.1016/j.chroma.2012.03.088] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
129 Do C, DeAguero J, Brearley A, Trejo X, Howard T, Escobar GP, Wagner B. Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution. Kidney360 2020;1:561-8. [PMID: 34423308 DOI: 10.34067/kid.0000272019] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
130 Dill KE, George E, Abbara S, Cummings K, Francois CJ, Gerhard-Herman MD, Gornik HL, Hanley M, Kalva SP, Kirsch J, Kramer CM, Majdalany BS, Moriarty JM, Oliva IB, Schenker MP, Strax R, Rybicki FJ. ACR appropriateness criteria imaging for transcatheter aortic valve replacement. J Am Coll Radiol 2013;10:957-65. [PMID: 24183748 DOI: 10.1016/j.jacr.2013.09.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
131 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
132 Hope TA, Herfkens RJ, Denianke KS, Leboit PE, Hung Y, Weil E. Nephrogenic Systemic Fibrosis in Patients With Chronic Kidney Disease Who Received Gadopentetate Dimeglumine: . Investigative Radiology 2009;44:135-9. [DOI: 10.1097/rli.0b013e31819343ba] [Cited by in Crossref: 46] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
133 Weller A, Barber JL, Olsen ØE. Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol 2014;29:1927-37. [DOI: 10.1007/s00467-013-2636-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
134 Altun E, Semelka RC, Cakit C. Nephrogenic systemic fibrosis and management of high-risk patients. Acad Radiol. 2009;16:897-905. [PMID: 19375360 DOI: 10.1016/j.acra.2009.01.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
135 Roditi G, Maki JH, Oliveira G, Michaely HJ. Renovascular imaging in the NSF Era. J Magn Reson Imaging. 2009;30:1323-1334. [PMID: 19937926 DOI: 10.1002/jmri.21977] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
136 Giorgi H, Ammerman J, Briffaux J, Fretellier N, Corot C, Bourrinet P. Non-clinical safety assessment of gadoterate meglumine (Dotarem®) in neonatal and juvenile rats. Regulatory Toxicology and Pharmacology 2015;73:960-70. [DOI: 10.1016/j.yrtph.2015.09.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
137 Qian X, Han X, Yu L, Xu T, Chen Y. Manganese‐Based Functional Nanoplatforms: Nanosynthetic Construction, Physiochemical Property, and Theranostic Applicability. Adv Funct Mater 2019;30:1907066. [DOI: 10.1002/adfm.201907066] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
138 Shellock FG, Spinazzi A. MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2008;191:1129-1139. [PMID: 18806155 DOI: 10.2214/ajr.08.1038.1] [Cited by in Crossref: 154] [Cited by in F6Publishing: 25] [Article Influence: 11.8] [Reference Citation Analysis]
139 Rutherford E, Mangion K, McComb C, Bell E, Cockburn S, Talle M, Roditi G, Welsh P, Woodward R, Radjenovic A, Struthers AD, Jardine AG, Berry C, Patel RK, Mark PB. Myocardial changes in incident haemodialysis patients over 6-months: an observational cardiac magnetic resonance imaging study. Sci Rep 2017;7:13976. [PMID: 29070834 DOI: 10.1038/s41598-017-14481-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
140 Bernstein EJ, Schmidt-lauber C, Kay J. Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure. Best Practice & Research Clinical Rheumatology 2012;26:489-503. [DOI: 10.1016/j.berh.2012.07.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
141 Nakamura K, Miyazaki M, Kuroki K, Yamamoto A, Hiramine A, Admiraal-behloul F. Noncontrast-enhanced peripheral MRA: Technical optimization of flow-spoiled fresh blood imaging for screening peripheral arterial diseases. Magn Reson Med 2011;65:595-602. [DOI: 10.1002/mrm.22614] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
142 Ciura VA, Lee MJ, Schemmer DC. MRA: Current Applications in Body Vascular Imaging. Can Assoc Radiol J 2009;60:133-42. [DOI: 10.1016/j.carj.2009.05.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 Bruce R, Wentland AL, Haemel AK, Garrett RW, Sadowski DR, Djamali A, Sadowski EA. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. Invest Radiol. 2016;51:701-705. [PMID: 26885631 DOI: 10.1097/rli.0000000000000259] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
144 Pine J, Rajaganeshan R, Baker R, Lewington A, Patel J, Menon K, Kessel D, Ahmad N. Early Postoperative Renal Vein Stenosis after Renal Transplantation: A Report of Two Cases. Journal of Vascular and Interventional Radiology 2010;21:303-4. [DOI: 10.1016/j.jvir.2009.10.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
145 Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ. Gadolinium-based contrast agents: A comprehensive risk assessment. J Magn Reson Imaging 2017;46:338-53. [PMID: 28083913 DOI: 10.1002/jmri.25625] [Cited by in Crossref: 168] [Cited by in F6Publishing: 104] [Article Influence: 42.0] [Reference Citation Analysis]
146 Edwards BJ, Laumann AE, Nardone B, Miller FH, Restaino J, Raisch DW, McKoy JM, Hammel JA, Bhatt K, Bauer K, Samaras AT, Fisher MJ, Bull C, Saddleton E, Belknap SM, Thomsen HS, Kanal E, Cowper SE, Abu Alfa AK, West DP. Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report. Br J Radiol 2014;87:20140307. [PMID: 25230161 DOI: 10.1259/bjr.20140307] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
147 Penfield JG, Reilly RF. Gadolinium and Nephrogenic Systemic Fibrosis: Have We Overreacted?: GADOLINIUM AND NEPHROGENIC SYSTEMIC FIBROSIS. Seminars in Dialysis 2011;24:480-6. [DOI: 10.1111/j.1525-139x.2011.00945.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
148 Hoppe H, Spagnuolo S, Froehlich JM, Nievergelt H, Dinkel H, Gretener S, Thoeny HC. Retrospective analysis of patients for development of nephrogenic systemic fibrosis following conventional angiography using gadolinium-based contrast agents. Eur Radiol 2010;20:595-603. [DOI: 10.1007/s00330-009-1586-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
149 Wagner B, Drel V, Gorin Y. Pathophysiology of gadolinium-associated systemic fibrosis. Am J Physiol Renal Physiol 2016;311:F1-F11. [PMID: 27147669 DOI: 10.1152/ajprenal.00166.2016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 6.2] [Reference Citation Analysis]
150 Newton BB, Jimenez SA. Mechanism of NSF: New evidence challenging the prevailing theory. J Magn Reson Imaging 2009;30:1277-83. [PMID: 19937925 DOI: 10.1002/jmri.21980] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
151 Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014;69:661-668. [PMID: 24582176 DOI: 10.1016/j.crad.2014.01.003] [Cited by in Crossref: 78] [Cited by in F6Publishing: 40] [Article Influence: 11.1] [Reference Citation Analysis]
152 Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 2009;30:1313-22. [PMID: 19937937 DOI: 10.1002/jmri.21983] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
153 Bak SH, Roh HG, Moon WJ, Choi JW, An HS. Appropriate Minimal Dose of Gadobutrol for 3D Time-Resolved MRA of the Supra-Aortic Arteries: Comparison with Conventional Single-Phase High-Resolution 3D Contrast-Enhanced MRA. AJNR Am J Neuroradiol 2017;38:1383-90. [PMID: 28473338 DOI: 10.3174/ajnr.A5176] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
154 Cowper SE. Gadolinium – is it to blame? J Cutan Pathol 2008;35:520-2. [DOI: 10.1111/j.1600-0560.2008.01027.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
155 Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis. 2011;18:188-198. [PMID: 21531325 DOI: 10.1053/j.ackd.2011.03.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
156 Penfield JG. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. Pediatr Nephrol 2008;23:2121-9. [PMID: 18543004 DOI: 10.1007/s00467-008-0862-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
157 Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, Bauer WR. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:31. [PMID: 22607376 DOI: 10.1186/1532-429X-14-31] [Cited by in Crossref: 62] [Cited by in F6Publishing: 19] [Article Influence: 6.9] [Reference Citation Analysis]
158 Abdel-Kader K, Patel PR, Kallen AJ, Sinkowitz-Cochran RL, Bolton WK, Unruh ML. Nephrogenic systemic fibrosis: a survey of nephrologists' perceptions and practices. Clin J Am Soc Nephrol 2010;5:964-71. [PMID: 20299369 DOI: 10.2215/CJN.00140110] [Cited by in Crossref: 7] [Article Influence: 0.6] [Reference Citation Analysis]
159 Emre T, Kiliçkesmez Ö, Büker A, İnal BB, Doğan H, Ecder T. Renal function and diffusion-weighted imaging: a new method to diagnose kidney failure before losing half function. Radiol Med 2016;121:163-72. [PMID: 26392392 DOI: 10.1007/s11547-015-0579-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
160 Morris MF, Zhang Y, Zhang H, Prowda JC, Silvers DN, Fawwaz RA, Prince MR. Features of nephrogenic systemic fibrosis on radiology examinations. AJR Am J Roentgenol 2009;193:61-9. [PMID: 19542396 DOI: 10.2214/AJR.08.1352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Alabousi M, Davenport MS. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease and the Risk of Nephrogenic Systemic Fibrosis: Radiology In Training. Radiology 2021;300:279-84. [PMID: 34060939 DOI: 10.1148/radiol.2021210044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Jain R, Levine M. Correction to the relative risk calculation for gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis. Radiology 2010;255:307-8; author reply 308. [PMID: 20308469 DOI: 10.1148/radiol.091726] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
163 Sun W, Zhang J, Zhang C, Wang P, Peng C, Shen M, Shi X. Construction of Hybrid Alginate Nanogels Loaded with Manganese Oxide Nanoparticles for Enhanced Tumor Magnetic Resonance Imaging. ACS Macro Lett 2018;7:137-42. [DOI: 10.1021/acsmacrolett.7b00999] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
164 Marckmann P. Nephrogenic systemic fibrosis: epidemiology update: . Current Opinion in Nephrology and Hypertension 2008;17:315-9. [DOI: 10.1097/mnh.0b013e3282f4b605] [Cited by in Crossref: 32] [Article Influence: 2.5] [Reference Citation Analysis]
165 Mihai G, Chung Y, Kariisa M, Raman SV, Simonetti OP, Rajagopalan S. Initial feasibility of a multi-station high resolution three-dimensional dark blood angiography protocol for the assessment of peripheral arterial disease. J Magn Reson Imaging 2009;30:785-93. [DOI: 10.1002/jmri.21923] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
166 Do JG, Kim YB, Lee DG, Hwang JH. A case of delayed onset nephrogenic systemic fibrosis after gadolinium based contrast injection. Ann Rehabil Med 2012;36:880-6. [PMID: 23342325 DOI: 10.5535/arm.2012.36.6.880] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
167 Mark PB, Doyle A, Blyth KG, Patel RK, Weir RA, Steedman T, Foster JE, Dargie HJ, Jardine AG. Vascular function assessed with cardiovascular magnetic resonance predicts survival in patients with advanced chronic kidney disease. J Cardiovasc Magn Reson 2008;10:39. [PMID: 18706114 DOI: 10.1186/1532-429X-10-39] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
168 Weigle JP, Broome DR. Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature. Skeletal Radiol 2008;37:457-64. [DOI: 10.1007/s00256-008-0464-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]